Description: NurExone Biologic Inc., a pharmaceutical company, engages in the development of novel, biologic, and minimal-invasive treatment for the spinal cord and traumatic brain injury. It develops a biological extracellular vesicles-based technology drug platform to treat damage in the central nerve system. The company was founded in 2020 and is based in Toronto, Canada.
Home Page: nurexone.com
NRX Technical Analysis
1 First Canadian Place
Toronto,
ON
M5X 1G5
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Yoram Drucker | Co-Founder, VP of Strategic Development & Chairman |
| Dr. Lior Shaltiel Ph.D. | CEO & Director |
| Mr. Eran Ovadya M.B.A. | CFO, Financial Director & Secretary |
| Mr. Gabriel Eldor | Co-Founder & Business Development Manager |
| Dr. Shulamit Levenberg Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Daniel Offen Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Prof. Nahshon Knoller M.D. | Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board |
| Dr. Ina Sarel Ph.D. | Head of CMC, Quality & Regulation |
| Mr. Nirit Drori-Carmi M.Sc. | Head of Bioprocess Development |
| Dr. Limor Chen Ph.D. | Head of Scientific Collaboration & External Partnerships |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.3463 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |